Researchers from McMaster University and the Firestone Institute for Respiratory Health at St. Joseph’s Healthcare Hamilton, together with colleagues at other partnering institutions, have developed a new method to treat severe asthma.
In a study of over 200 participants with severe asthma, the new treatment was shown to have improved asthma symptoms and lung function, while reducing the need for corticosteroids by up to 70%.
According to Statistics Canada, eight per cent of Canadians aged 12 or older – approximately 2.4 million people – have been diagnosed with asthma. Of that, approximately 25% are considered to be severe cases of asthma.
Current treatments for severe asthma often include high doses of corticosteroids, such as prednisone, to control exacerbations. Reducing the need for corticosteroids with alternative treatments is preferable, since these medications are associated with serious side effects from prolonged use – including multi-organ toxicities and immunosuppression.
Parameswaran Nair, professor of medicine at McMaster and staff respirologist at St. Joseph’s Healthcare Hamilton, along with a team of researchers found that an antibody called dupilumab is effective in treating severe asthma in place of high doses of prednisone.
The results were published in the New England Journal of Medicine, one of the world’s most influential medical publications.
Researchers sought participants who had been using oral corticosteroids (prednisone) to treat severe asthma for at least six months prior to the study. In addition to their standard regimen of corticosteroids, patients received either dupilumab or a placebo during the 24 week trial. The corticosteroid dose was gradually reduced during weeks four to 20, and maintained at a low level for the final four weeks.
“The ability of dupilumab to increase lung function as markedly as it did in this study, even in the face of [corticosteroid] withdrawal, indicates that it appears to be inhibiting key drivers of lung inflammation,” the researchers noted.
Dupilumab works to treat asthma by blocking two specific proteins (called interleukin-4 and interleukin-13) that are associated with inflammation of the airways.
This technique was based on Nair’s previous research, (published in the New England Journal of Medicine in 2009 and in 2017). Those studies found that blocking another protein, interleukin-5, allowed patients with high eosinophil levels in their blood and airways to reduce their corticosteroid dose. Eosinophils are a type of white blood cell involved with the production of interleukins. High eosinophil levels are directly linked to an increased risk of severe asthma.
Unlike the previous studies, dupilumab was shown to be effective regardless of patients’ eosinophil levels. Despite the reduced prednisone dose, patients in this study not only experienced a decrease in asthma exacerbations, but their lung function also improved significantly.
“Ultimately, our goal is to find new treatment pathways that allow us to circumvent the use of corticosteroids,” said Nair.
“Since dupilumab showed a significant improvement on asthma control regardless of eosinophil levels, we may be able to use this treatment for a wider range of patients than we previously thought possible. This might be due to the broad effects on inflammation in asthma of the two proteins that we were able to block with dupilumab. The treatment was not associated with any serious side effects.”
The Latest on: Asthma
via Google News
The Latest on: Asthma
- U of C researchers discover new way to treat asthma attacks on October 6, 2018 at 11:15 am
After five years of ongoing research, scientists at the University of Calgary have discovered a new way to help asthma patients breath more easily during an allergen-induced asthma attack. "It's promi... […]
- Fundraiser tonight for Bridgeport girl who died of asthma attack on October 5, 2018 at 9:55 am
Today is “Dream Day” at a Bridgeport elementary school to commemorate Dream White, a 10-year-old student there who passed away over the weekend. Family members say Dream was a serious student ... […]
- Global Asthma Medication Market Research Report for 2018 scrutinized in new research on October 5, 2018 at 6:40 am
The Asthma Medication Market was valued at 5200 Million US$ in 2018 and is projected to reach 8040 Million US$ by 2023, at a CAGR of 5.6% during the forecast period. This Global Asthma Medication Mark... […]
- Study analyzes role of environmental exposures in pediatric asthma control on October 5, 2018 at 12:15 am
A study from the Nationwide Children's Hospital analyzed environmental exposures, like pet and secondhand smoke, to determine if they have a role in asthma control among children whose asthma is manag... […]
- Climate change and natural disasters contributing to rise allergy in and asthma cases on October 4, 2018 at 10:57 pm
Asthma and allergy cases have risen 12 percent in the last decade, as well as food allergies and other sensitivities. Researchers are still determining the exact reason, but climate change and natural ... […]
- Why mold is most dangerous for those with asthma, allergies on October 4, 2018 at 10:38 am
Why mold is most dangerous for those with asthma, allergies Living in a building with mold isn’t ever healthy, but it’s most dangerous for those who have asthma or mold allergies, according to health ... […]
- Have asthma and a pet? Re-homing your cat or dog may not be necessary if asthma guidelines are followed on October 4, 2018 at 9:14 am
SAN ANTONIO, Oct. 4, 2018 /PRNewswire/ -- A study from the Nationwide Children's Hospital analyzed environmental exposures, like pet and secondhand smoke, to determine if they have a role in asthma co... […]
- Have asthma and a pet? Re-homing your cat or dog may not be necessary on October 4, 2018 at 7:26 am
A study analyzed environmental exposures, like pet and secondhand smoke, to determine if they have a role in asthma control among children whose asthma is managed per NAEPP (EPR-3) guidelines. […]
- AireSone Junior helps parents stop worrying about their child's asthma on October 3, 2018 at 6:52 pm
Asthma is the most common chronic condition in children, affecting an estimated 6.1 million children in the US, according to the American Lung Association. It's also the third leading cause of hospita... […]
via Bing News